Sugi Predict

Sugi Predict / Targets / F2RL1

F2RL1

Proteinase-activated receptor 2 · P55085 · F2RL1 on Sugi Atlas →

12,093 patent compounds predicted against F2RL1, 5,816 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL696418 SCHEMBL696418 0.61 20/20
SCHEMBL714299 SCHEMBL714299 0.59 20/20
SCHEMBL697440 SCHEMBL697440 0.54 20/20
SCHEMBL697817 SCHEMBL697817 0.53 20/20
SCHEMBL697637 SCHEMBL697637 0.53 20/20
SCHEMBL696724 SCHEMBL696724 0.60 19/20
SCHEMBL954700 SCHEMBL954700 0.51 19/20
SCHEMBL698030 SCHEMBL698030 0.52 18/20
SCHEMBL954072 SCHEMBL954072 0.58 17/20
SCHEMBL953691 SCHEMBL953691 0.51 17/20
SCHEMBL1485149 SCHEMBL1485149 0.45 17/20
SCHEMBL2205006 SCHEMBL2205006 0.48 15/20
SCHEMBL698055 SCHEMBL698055 0.46 15/20
SCHEMBL697577 SCHEMBL697577 0.43 15/20
SCHEMBL697224 SCHEMBL697224 0.47 14/20
SCHEMBL1573055 SCHEMBL1573055 0.44 14/20
SCHEMBL3417395 SCHEMBL3417395 0.43 14/20
SCHEMBL698494 SCHEMBL698494 0.43 14/20
SCHEMBL957611 SCHEMBL957611 0.42 14/20
SCHEMBL917944 SCHEMBL917944 0.39 14/20

Clinical trials — most relevant to F2RL1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Vorapaxar on Thrombin Generation and Coagulability PHASE4COMPLETED
Effects of Rivaroxaban on Vascular FMD in Patients With Stable Atherosclerotic Vascular Diseases PHASE4COMPLETED
Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor PHASE4COMPLETED
Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography PHASE4UNKNOWN
Bradykinin Receptor Antagonism During Cardiopulmonary Bypass PHASE2/PHASE3COMPLETED
suPAR to Guide Antibiotics in Emergency Department PHASE2/PHASE3UNKNOWN
Effect of Hyperglycemia in PAI-1 Activity and the Relationship With Outcome in Severe Sepsis and Septic Shock PHASE2/PHASE3COMPLETED
Ramatroban/Montelukast Versus Montelukast/Placebo on the Early Allergic Reaction in Asthma Sensitive to House Dust Mite PHASE2/PHASE3WITHDRAWN
Clinical Trial With Aprotinin in the Acute Respiratory Distress Syndrome Treatment PHASE3NOT_YET_RECRUITING
Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease PHASE2COMPLETED
Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome PHASE1COMPLETED
Combination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising Treatment for COVID-19 Infection- and Its Inflammatory Complications PHASE1UNKNOWN
SerpinB3 Expression, PAR2 and SCCA-PD Polymorphism in Acute Respiratory Distress Syndrome nanRECRUITING
Impact of Combination of Clopidogrel With Aspirin on Postoperative Bleeding in Coronary Surgical Patients nanCOMPLETED
Kinetics of Nasal Cytokine Responses to Mechanical Stimulation nanCOMPLETED
Thrombin Regulated Platelet Activation nanCOMPLETED
The Evaluation of Hemostasis in Hospitalized COVID-19 Patients nanUNKNOWN
PAR Regulation of Platelet Function in Diabetic Patients nanCOMPLETED
SuPAR in Adult Patients With Covid-19 nanCOMPLETED
Assessment of the Soluble Urokinase Plasminogen Activator Receptor in Non-cardiac Surgery (SPARSE) nanCOMPLETED
Disorders of the Acute Phase Response Following Trauma and Invasive Surgery nanENROLLING_BY_INVITATION
FGL2/Fibroleukin and Hepatitis C Virus Recurrence Post Liver Transplantation nanUNKNOWN
Study of the Vascular Response to Percutaneous Coronary Intervention in Patients With Non-ST-elevation Acute Coronary Syndromes Using Intravascular Blood Sampling nanWITHDRAWN
Oxidative Stress and Haemostasis Abnormalities in Cirrhosis nanUNKNOWN
The Severe Asthma Research Program III-Boston Clinical Site nanCOMPLETED
Inflammation, Platelets and Sickle Cell Disease nanACTIVE_NOT_RECRUITING
The Role of Platelet Surface α2β1 Integrin Expression as a Risk Factor in Thrombotic and/or Bleeding Complications nanCOMPLETED
Association of Circulating ACE2 Levels With COVID-19 nanCOMPLETED
In-vivo Thrombus Imaging With 18F-GP1, a Novel Platelet PET Radiotracer nanCOMPLETED
Myocardial Injury and Dysfunction Associated With COVID-19 Vaccination nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a F2RL1 binder may also engage these)

ProteinNameSimilarity
P55086 — 1.000 P55086 →
Q2HJA4 — 0.997 Q2HJA4 →
Q63645 — 0.992 Q63645 →
F2R Proteinase-activated receptor 1 0.983 landscape →
P30558 — 0.982 P30558 →
Q8BLG2 — 0.980 Q8BLG2 →
P56488 — 0.978 P56488 →
A7YY44 — 0.978 A7YY44 →
Q00991 — 0.978 Q00991 →
LPAR4 Lysophosphatidic acid receptor 4 0.977 landscape →
Q9ESG6 — 0.975 Q9ESG6 →
P26824 — 0.974 P26824 →
Q9CPV9 — 0.974 Q9CPV9 →
Q4G072 — 0.973 Q4G072 →
P47749 — 0.971 P47749 →
Q920E1 — 0.971 Q920E1 →
P49652 — 0.970 P49652 →
P34996 — 0.970 P34996 →
P48042 — 0.970 P48042 →
P49650 — 0.970 P49650 →
Q5ZI82 — 0.969 Q5ZI82 →
O00254 — 0.969 O00254 →
Q924T8 — 0.968 Q924T8 →
Q3SX17 — 0.968 Q3SX17 →
P59902 — 0.968 P59902 →
P49651 — 0.968 P49651 →
P2RY1 P2Y purinoceptor 1 0.967 landscape →
LPAR6 Lysophosphatidic acid receptor 6 0.967 landscape →
D4A7K7 — 0.967 D4A7K7 →
Q58D85 — 0.966 Q58D85 →